Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus.

Michael J HaddStephen E BienhoffSusan E LittleSamuel GellerJennifer Ogne-StevensonThomas J DupreeJ Catharine Scott-Moncrieff

Published in: Journal of veterinary internal medicine (2023)

Bexagliflozin decreased hyperglycemia and observed clinical signs in cats newly diagnosed with DM. As a once-daily PO medication, bexagliflozin may simplify management of DM in cats.

Keyphrases

newly diagnosed
glycemic control
randomized controlled trial
systematic review
physical activity
healthcare
type diabetes
emergency department
adipose tissue
adverse drug
skeletal muscle
insulin resistance